Opko Health Inc (OPK)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.25B
Last updated: Nov 17, 2026 at 11:06 AM ET
Opko Health Inc (OPK) Earnings: Report Dates and Results
Opko Health (OPK) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Opko Health reported EPS of -$0.05, above the -$0.07 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OPK has an expected report date of Feb 24, 2027.
OPK Earnings Call
The latest OPK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, OPK beat 19, missed 13 and matched 8. Revenue for the quarter ended Sep 30, 2026 was $65.41M, up 15.9% from $56.42M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.07 | -$0.08 - -$0.05 | +28.57% | Beat | -266.7% | 3 | 1 up, 0 down | Nov 4, 2026 | $65.41M |
| Jun 30, 2026 | -$0.01 | -$0.08 | N/A | +87.50% | Beat | N/A | 1 | 0 up, 0 down | Jul 27, 2026 | $163.58M |
| Mar 31, 2026 | -$0.07 | -$0.07 | -$0.08 - -$0.05 | 0.00% | In line | N/A | 6 | 2 up, 2 down | Apr 28, 2026 | $124.20M |
| Dec 31, 2025 | -$0.04 | -$0.07 | -$0.07 - -$0.07 | +42.86% | Beat | -500.0% | 1 | 1 up, 0 down | Feb 26, 2026 | $148.45M |
| Sep 30, 2025 | $0.03 | -$0.04 | -$0.11 - $0.03 | +175.00% | Beat | 0.0% | 6 | 2 up, 2 down | Oct 29, 2025 | $56.42M |
| Jun 30, 2025 | -$0.08 | -$0.10 | -$0.10 - -$0.10 | +20.00% | Beat | N/A | 1 | 0 up, 0 down | Jul 31, 2025 | $156.81M |
| Mar 31, 2025 | -$0.09 | -$0.11 | -$0.11 - -$0.11 | +18.18% | Beat | N/A | 1 | 0 up, 0 down | Apr 30, 2025 | $149.95M |
| Dec 31, 2024 | $0.01 | -$0.10 | N/A | +110.00% | Beat | N/A | N/A | 0 up, 0 down | Feb 27, 2025 | $183.64M |
| Sep 30, 2024 | $0.03 | -$0.09 | -$0.11 - -$0.07 | +133.33% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2024 | $173.63M |
| Jun 30, 2024 | -$0.01 | -$0.09 | -$0.12 - -$0.07 | +88.89% | Beat | N/A | 6 | 0 up, 0 down | Aug 7, 2024 | $182.19M |
| Mar 31, 2024 | -$0.12 | -$0.09 | -$0.14 - -$0.06 | -33.33% | Miss | N/A | 6 | 0 up, 0 down | May 7, 2024 | $173.69M |
| Dec 31, 2023 | -$0.09 | -$0.09 | -$0.10 - -$0.08 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Feb 27, 2024 | $181.91M |
| Sep 30, 2023 | -$0.11 | -$0.10 | -$0.16 - -$0.08 | -10.00% | Miss | N/A | 6 | 0 up, 0 down | Nov 6, 2023 | $178.59M |
| Jun 30, 2023 | -$0.03 | -$0.07 | -$0.13 - $0.02 | +57.14% | Beat | N/A | 6 | 0 up, 0 down | Aug 3, 2023 | $265.42M |
| Mar 31, 2023 | -$0.02 | -$0.08 | -$0.14 - -$0.02 | +75.00% | Beat | N/A | 6 | 0 up, 0 down | May 3, 2023 | $237.58M |
| Dec 31, 2022 | -$0.11 | -$0.11 | -$0.16 - -$0.08 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Feb 23, 2023 | $185.34M |
| Sep 30, 2022 | -$0.11 | -$0.08 | -$0.13 - -$0.06 | -37.50% | Miss | -375.0% | 5 | 0 up, 0 down | Nov 8, 2022 | $179.74M |
| Jun 30, 2022 | -$0.14 | $0.03 | -$0.06 - $0.07 | -566.67% | Miss | N/A | 5 | 0 up, 0 down | Aug 4, 2022 | $309.89M |
| Mar 31, 2022 | -$0.08 | -$0.06 | -$0.11 - -$0.01 | -33.33% | Miss | -260.0% | 5 | 0 up, 0 down | May 9, 2022 | $329.22M |
| Dec 31, 2021 | -$0.11 | -$0.02 | -$0.03 - -$0.01 | -450.00% | Miss | -320.0% | 5 | 0 up, 0 down | Feb 24, 2022 | $401.33M |
| Sep 30, 2021 | $0.04 | -$0.01 | -$0.03 - $0.01 | +500.00% | Beat | 0.0% | 5 | N/A | Oct 28, 2021 | $385.81M |
| Jun 30, 2021 | -$0.03 | $0.02 | $0.00 - $0.03 | -250.00% | Miss | -160.0% | 5 | N/A | Jul 29, 2021 | $442.41M |
| Mar 31, 2021 | $0.05 | $0.05 | $0.04 - $0.06 | 0.00% | In line | N/A | 5 | N/A | Apr 28, 2021 | $545.16M |
| Dec 31, 2020 | $0.05 | $0.04 | $0.02 - $0.07 | +25.00% | Beat | N/A | 5 | N/A | Feb 18, 2021 | $494.68M |
| Sep 30, 2020 | $0.04 | $0.04 | $0.04 - $0.06 | 0.00% | In line | N/A | 5 | N/A | Oct 29, 2020 | $428.06M |
| Jun 30, 2020 | $0.05 | -$0.07 | -$0.10 - -$0.02 | +171.43% | Beat | N/A | 5 | N/A | Jul 30, 2020 | $301.21M |
| Mar 31, 2020 | -$0.09 | -$0.09 | -$0.09 - -$0.08 | 0.00% | In line | N/A | 4 | N/A | May 6, 2020 | $211.47M |
| Dec 31, 2019 | -$0.18 | -$0.09 | -$0.10 - -$0.08 | -100.00% | Miss | N/A | 4 | N/A | Feb 26, 2020 | $224.34M |
| Sep 30, 2019 | -$0.11 | -$0.09 | -$0.10 - -$0.08 | -22.22% | Miss | N/A | 3 | N/A | Nov 5, 2019 | $228.77M |
| Jun 30, 2019 | -$0.11 | -$0.11 | -$0.12 - -$0.10 | 0.00% | In line | N/A | 3 | N/A | Aug 7, 2019 | $226.37M |
| Mar 31, 2019 | -$0.13 | -$0.11 | -$0.13 - -$0.03 | -18.18% | Miss | N/A | 3 | N/A | May 7, 2019 | $222.45M |
| Dec 31, 2018 | -$0.09 | -$0.09 | -$0.10 - -$0.07 | 0.00% | In line | N/A | 3 | N/A | Feb 27, 2019 | $221.85M |
| Sep 30, 2018 | -$0.05 | -$0.06 | -$0.11 - -$0.05 | +16.67% | Beat | N/A | 5 | N/A | Nov 9, 2018 | $249.81M |
| Jun 30, 2018 | -$0.03 | -$0.07 | -$0.10 - -$0.02 | +57.14% | Beat | N/A | 6 | N/A | Aug 7, 2018 | $263.69M |
| Mar 31, 2018 | -$0.08 | -$0.13 | -$0.16 - -$0.10 | +38.46% | Beat | N/A | 5 | N/A | May 8, 2018 | $254.91M |
| Dec 31, 2017 | -$0.32 | -$0.08 | -$0.10 - -$0.05 | -300.00% | Miss | N/A | 6 | N/A | Mar 1, 2018 | $943.69M |
| Sep 30, 2017 | -$0.08 | -$0.05 | -$0.07 - -$0.03 | -60.00% | Miss | N/A | 6 | N/A | Nov 8, 2017 | $246.04M |
| Jun 30, 2017 | -$0.03 | -$0.05 | -$0.07 - -$0.03 | +40.00% | Beat | N/A | 5 | N/A | Aug 8, 2017 | $292.60M |
| Mar 31, 2017 | -$0.06 | -$0.04 | N/A | -50.00% | Miss | N/A | N/A | N/A | May 9, 2017 | $266.38M |
| Dec 31, 2016 | -$0.02 | -$0.04 | N/A | +50.00% | Beat | -789.7% | N/A | N/A | Mar 1, 2017 | $171.32M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.18, after -$0.09 the year before. It was -$0.09 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.18 | N/A |
| Dec 31, 2024 | -$0.09 | N/A |
| Dec 31, 2023 | -$0.25 | N/A |
| Dec 31, 2022 | -$0.44 | N/A |
| Dec 31, 2021 | -$0.05 | -200.0% |
| Dec 31, 2020 | $0.05 | N/A |
| Dec 31, 2019 | -$0.53 | N/A |
| Dec 31, 2018 | -$0.25 | N/A |
| Dec 31, 2017 | -$0.49 | N/A |
| Dec 31, 2016 | -$0.09 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,418 | 10 | |
| 2026Q2 | Jun 30, 2026 | 6,154 | 12 | |
| 2025Q4 | Dec 31, 2025 | 5,401 | 11 | |
| 2025Q3 | Sep 30, 2025 | 6,379 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,538 | 10 | |
| 2025Q1 | Mar 31, 2025 | 5,384 | 12 | |
| 2024Q4 | Dec 31, 2024 | 4,930 | 11 | |
| 2024Q3 | Sep 30, 2024 | 5,540 | 10 |
2026Q3 Earnings Call
Opening remarks
Vivian Cervantes Investor Relations, Alliance Advisors Thank you, operator. Good afternoon, everyone. Thank you for joining us on today's call to discuss OPKO Health's financial results for the third quarter of 2026. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking and, as such, are subject to risks and uncertainties that could materially affect the company's results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2025. Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 4, 2026. Except as required by law, OPKO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Regarding the format of today's call, Dr. Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Dr. Elias Zerhouni, President and Vice Chairman, will then review OPKO's pipeline and business. After that, Adam Logal, OPKO's Chief Financial Officer, will review the new LabCorp transaction, the company's third-quarter financial results, and its outlook. We will then open the line for questions. I'd now like to turn the call over to Dr. Frost.
Phillip Frost Chairman and CEO Good afternoon, and thank you for joining us today. The LabCorp transaction marks a defining moment for OPKO. Once closed, it will complete our exit from clinical laboratory services, sharpen our focus, and allow our management attention, our people, and our capital to focus on biotech innovation and our global products business. Adam will provide the transaction and financial details later. This reflects the approach we have applied throughout OPKO's history: build differentiated businesses and assets, validate their value, monetize them at the right time, and redeploy capital into our highest-return opportunities. Going forward, OPKO is centered on two continuing businesses. Innovative Biotech brings together ModeX and OPKO Biologics, with a broad portfolio across oncology, immunology, infectious disease, and endocrinology. Global Products includes Rayaldee and our international pharmaceutical operations, with established commercial capabilities and recurring cash flow. The third quarter was one of steady execution across our pipeline. ModeX expanded its clinical activity, completed enrollment in the planned Phase I cohorts for MDX-2301, and continued advancing our differentiated in vivo CAR-T platform toward the clinic. Elias will discuss that progress. The collaborations with Merck, Regeneron, Entera Bio, and BARDA continue to add scientific capability, external validation, and nondilutive support, while NGENLA, Rayaldee, and our international operations contribute to the strength of the business.
Frequently Asked Questions About OPK
When is Opko Health's next earnings date?
Opko Health's next earnings report is expected for Feb 24, 2027.
Did OPK beat earnings estimates last quarter?
Yes. Opko Health reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.07 estimate, a 28.57% surprise.
What EPS do analysts expect from OPK next quarter?
The consensus EPS estimate for Opko Health for the quarter ending Dec 31, 2026 is -$0.07 from 7 analysts, with estimates from -$0.11 to -$0.05.
How often does OPK beat earnings estimates?
Opko Health beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +60.26%.
OPK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts